Brokerages Set Moderna, Inc. (NASDAQ:MRNA) PT at $79.50

Shares of Moderna, Inc. (NASDAQ:MRNA) have earned a consensus recommendation of “Hold” from the twenty-two ratings firms that are covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a sell recommendation, twelve have assigned a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $78.83.

A number of research analysts have weighed in on the company. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 target price on shares of Moderna in a report on Thursday, September 19th. Piper Sandler reaffirmed an “overweight” rating and set a $69.00 price objective (down previously from $115.00) on shares of Moderna in a research note on Monday, November 18th. UBS Group decreased their target price on shares of Moderna from $108.00 to $96.00 and set a “buy” rating on the stock in a report on Wednesday. Bank of America reissued an “underperform” rating and issued a $41.00 price target on shares of Moderna in a report on Tuesday, December 10th. Finally, Jefferies Financial Group decreased their price target on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a report on Tuesday, October 15th.

Insiders Place Their Bets

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in MRNA. Ashton Thomas Private Wealth LLC bought a new position in Moderna during the 2nd quarter valued at about $26,000. Plato Investment Management Ltd grew its holdings in Moderna by 230.4% in the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after purchasing an additional 288 shares during the last quarter. Larson Financial Group LLC boosted its holdings in Moderna by 1,753.1% in the second quarter. Larson Financial Group LLC now owns 593 shares of the company’s stock worth $70,000 after acquiring an additional 561 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in Moderna during the 2nd quarter worth approximately $75,000. Finally, Blue Trust Inc. raised its stake in Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after acquiring an additional 574 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Trading Down 9.2 %

NASDAQ:MRNA opened at $43.17 on Tuesday. Moderna has a 12 month low of $35.80 and a 12 month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The firm’s 50 day moving average is $42.99 and its 200 day moving average is $70.69. The stock has a market capitalization of $16.61 billion, a PE ratio of -7.42 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.39) EPS. Sell-side analysts expect that Moderna will post -9.3 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.